Clinical Trials Directory

Trials / Completed

CompletedNCT02032225

Generation of a Cellular Model of CADASIL From Skin Fibroblasts

Obtention d'un modèle Cellulaire de la Maladie CADASIL à Partir de Fibroblastes cutanés de Patients

Status
Completed
Phase
Study type
Observational
Enrollment
8 (actual)
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France · Other Government
Sex
All
Age
30 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy (CADASIL) is an archetypal small vessel disease of the brain caused by dominant mutations in the NOTCH3 receptor. Cardinal vascular lesions include deposition of granular osmiophilic material (GOM) within the basal lamina of smooth muscle cells, progressive smooth muscle cell loss, and fibrosis of the media. Pathogenic mutations alter the number of cysteine residues in the extracellular domain of NOTCH3 (Notch3 ECD), leading to its abnormal accumulation in the GOM deposits. Vascular smooth muscle cell has been identified as the primary target cell in this disease. Pathophysiological processes leading from NOTCH3 mutations to smooth muscle cell loss remain poorly understood. The investigators propose to study these mechanisms by reprogramming skin cells to become stem cells and then differentiating them to vascular smooth muscle cells. The hypothesis of this study is that the differentiated smooth muscle cells will display the characteristic features of CADASIL, ie, Notch3 ECD accumulation and GOM deposits.

Conditions

Interventions

TypeNameDescription
OTHERSkin biopsy

Timeline

Start date
2014-02-01
Primary completion
2015-02-11
Completion
2015-02-11
First posted
2014-01-09
Last updated
2025-05-16

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02032225. Inclusion in this directory is not an endorsement.